Nexus AG

Quarterly Report • Nov 12, 2012

Quarterly Report 30 September 2012

Letter to Our Stockholders

Dear Stockholders:

The NEXUS team confirmed our good development of the third quarter and again produced a good result. We recorded continued sales growth, substantial improvement of operating results and additional acquisitions of strategic corporate participating interests: We were able to provide very pleasing proof of the high level of performance of the organization with this result, and we are determined to confirm this good performance for the complete year.

In the first nine months of 2012, NEXUS AG recorded sales growth of approx. 14.0% and improved its result before taxes by approx. 20.0%. Growth and innovation at NEXUS remain in accord with further improved results. As in the past, we especially value continual and

healthy growth of our company, because our customers also evaluate this as a sign of responsible company management. Our continued considerable investments in software development are also a sign that we are betting on innovations and a long-term strategy.

The third quarter was characterized very strongly by activities in new projects. Large projects at customers such as GPR Rüsselsheim, Mühlen District Hospitals Minden, Canton of Sankt Gallen and German military hospitals are in the introductory phase and require a considerable share of our capacities. It is a question here of achieving our project goals and introducing our products successfully in these hospitals. We are especially faced with substantial implementation challenges in our large projects in Germany, and we will be judged on their success.

This strong development in new business also continued in the third quarter. Three additional hospitals decided in favor of NEXUS / HIS, and we have a total of 28 new customers as a result. This extraordinarily high number of new orders impressively documents the current special position of our product on the German market. We were able to acquire a total of 17 new customers in the NEXUS / DIS product area over the first nine months, and there were a total of 25 new customers in the QM area. Our business area of "long-term care" also started successfully with 20 new customers this year. We were able to acquire our first customers in the sterilization area in Austria and another ten orders in France.

Highlights 3rd Quarter - 2012 Development of Business

• • Strong increases in sales in the 3rd quarter
• • New, large HIS orders in Germany
• • Considerable project pressure due to new orders
• • Company acquisitions for expanding our business fields

We are using our currently strong starting position to orient NEXUS consistently to future growth

Organically and also to purchase strategically interesting companies and build up new business areas!

With our acquisitions of the past years, we have already invested in the new business fields of care of the elderly and sterilization. These are areas that were previously missing in our portfolio and from which we expect substantial growth potential.

In October of this year, we again purchased three companies and consequently accelerated our course for growth even more. Thanks to our investment in E&L GmbH, we have considerably expanded our diagnostic product portfolio by the areas of endoscopy, cardiology and oncology. The resultant product association has an exceptional position in diagnostic software on the market in the meantime and strengthens collaboration between NEXUS and other HIS suppliers on the market.

Acquisition of ASS.TEC GmbH strengthens our NEXUS / IT business field in the areas of "Process and SAP Consulting". The area of process consulting is especially gaining increasing significance for our customers in the healthcare field.

The purchase of CoM.MeD GmbH on 1 January 2013 mainly targets acquisition of technology for accounting in rehabilitation institutions. This is an area, which we did not previously master, but which is very much demand among health associations. The companies acquired in October are not consolidated in the report for the period until 30 September 2012.

The company acquisitions of the last months strengthen the position of NEXUS as full-service provider on the HIS market. At the same time, they create potential to offer other HIS providers an attractive product portfolio.

This is a development, which we introduced at an early stage with our diagnostic product line and with which we can position ourselves as a multiple product company with a uniform technology strategy.

Our product development is targeting the same goal. With the new products "NEXUS / OP", "NEXUS / RIS / PACS" and "NEXUS / PDMS", we developed and launched three new products on the market, which can both be used within NEXUS / HIS as well as stand-alones with other HIS. These are innovations, which target customer groups in addition to our own HIS market.

We also want to pursue the path of rapid organic and inorganic growth consistently further over the coming years. For this reason, we carried out a capital increase of 5.6% at the beginning of November with exclusion of subscription rights. This capital increase, which was over-subscribed multiple times, could be sold at approx. the market price and brought us another € 7.1 million in liquid assets. Even after our company acquisitions in October, we still have more than 16.0 million in cash reserves. Despite this, we decided to take this step of a small capital increase to enable us to act if there are opportunities for larger company acquisitions.

Dear Stockholders, NEXUS is an active and successful company. The attractiveness of our products and our numerous strategic measures provide us with impetus to work further intensively on the realization of our plans.

I want to thank you again for your trust! Warm regards,

Dr. Ingo Behrendt CEO - NEXUS AG

	09/30/2012		09/30/2011
	KEUR	%	KEUR
Sales	43,807	14.0	38,436
Sales Healthcare Software	40,993	16.0	35,332
Sales Healthcare Service	2,814	-9.3	3,104
Sales National	24,042	10.7	21,717
Sales International	19,765	18.2	16,719
Result of the period before tax	4,299	20.3	3,573
Result of the period	4,351	19.9	3,630
EBITDA	8,552	9.2	7,829
Result per Share	0,33	26.9	0,26
Investments in intangible and tangible assets	4,217	24.2	3,395
Depreciation	4,567	-0.6	4,596
Net Liquidity	23,840	10.5	21,572
Cash Flow from operative activities	7,633	-11.5	8,662
Employees (as of the reporting date)	482	3.0	468

Interim Annual Report

Sales/Result: Considerable Increase in the 3rd Quarter

NEXUS-Group sales increased in the first nine months of the year 2012 from KEUR 38,436 to KEUR 43,807 (+14.0%).

The Healthcare Software segment again generated strong growth. Sales increased by approx. 16.0% from KEUR 35,332 (Q3-2011) to KEUR 40,993. On the other hand, there was a reduction in sales in the area of Healthcare Service of 9.3%. The area recorded sales of KEUR 2,814 following KEUR 3,104 (Q3-2011). In a quarterly comparison, Group sales increased from KEUR 13,892 (Q2-2012) to KEUR 15,039 in Q3-2012 (+8.3%).

4

As a result, the share of sales outside of Germany increased overall from 43.5% to 45.1%. In these markets, sales totaled KEUR 19,765 following KEUR 16,719 in the previous year (+18.2%). The different growth rates in the regions are due to the invoicing cycles, but also to the consolidation of Domis AG, which operates in the Swiss market. Business increased by approx. 10.7% in Germany and reached KEUR 24,042 following KEUR 21,717.

NEXUS-Group was also able to continue its unabated positive development of results of the past years. The operating result before taxes improved by approx. 20.3% to KEUR 4,299. Earnings per share amounted to € 0.33 following € 0,26 in the previous year (+27%).

We were also able to improve the result before taxes of the third quarter 2012 substantially and achieved an increase of 45% with KEUR 1,321 following KEUR 914 (Q3-2011). This is a good result, especially against the background that the previous year's quarterly report was already very strong and the expenditures for company acquisitions are fully consolidated in the result.

The result after taxes increased by approx. 19.9% and reached KEUR 4,351 in the first nine months compared to KEUR 3,630 in the previous year KEUR 4,299 was achieved before taxes following the previous year's KEUR 3,573 (20.3%). The EBIT amounted to KEUR 3,985 following KEUR 3,369 (18.3%). The effective tax burdens remain slight as previously due to losses of the individual companies carried forward. Writeoffs as of 30 September 2012 are at the level of the previous year of € 4.6 million. Development costs were capitalized in the amount of € 3.3 million (Q3-2011: € 3.4 million) in the first nine months.

The EBITDA increased to KEUR 8,552 (+9.2%) in the first nine months following KEUR 7,829 (Q3-2011).

One-time effects and expenses for company acquisitions and share purchase of E&L GmbH, Erlangen, ASS.TEC GmbH, Villingen-Schwenningen and CoM.MeD GmbH, Barleben represented in their complete amount in the operating result.

Segment results (incl. shares of third parties) developed well. The Healthcare Service segment was substantially higher than the level of the previous year with a result before taxes of KEUR 3,801 compared to KEUR 3,112 (+22.1%). The Healthcare Service segment was also able to achieve an improved result of KEUR 498 (+8%) compared to the previous year (Q3-2011: KEUR 461).

The operative cash flow reached KEUR 7,663 as of 30 September 2012.

An operative cash flow of KEUR 7,663 was achieved in the first nine months of 2012 following KEUR 8,662 in the third quarter of 2011. The strong value of the previous year, we were able to achieve this year is not quite what was in particular the reduction of payments. Here were for individual major orders in the past year made significant advances, which we work through this year. The cash flow from investing activities amounted to KEUR 4,217. Liquid funds increased compared to the previous year by KEUR 2,268 to KEUR 23,840 (Q3-2011: KEUR 21,572). Securities are contained in this in the amount of 2.1 million euros. In the current year, dividends in the amount of EUR 1,428 were distributed; KEUR 234 were used for purchase of own shares.

The equity capital rate is 72%. NEXUS has no essential bank liabilities.

Highlights Q3 - 2012 Sales and Result

• • 14.0% sales increase by 30 September 2012 from € 32.4 million (Q3-2011) to € 43.8 million
• • 20.3% increase in result before taxes from € 3.57 million to € 4.29 million
• • Strong operative cash flow € 7.66 million
• • Increase of liquid assets compared to previous year by € 2.27 million to € 23.8 million

The balance sheet total increased from KEUR 80,419 to KEUR 83,749 compared to 31 December 2011. There are no essential bank liabilities.

Intangible assets, goodwill and balanced out deferred taxes add up to a total of KEUR 37,796 following KEUR 36,662 on 31 December 2011. This increase is especially due to the revaluation of the goodwill and technology of Domis AG, Altishofen (CH). Receivables decreased compared to 31 December 2011 from KEUR 14,364 to KEUR 13,322 (-7.3%).

Sales by divisions	01/01/ - 09/30/12	01/01/ - 09/30/11	∆ IN %	07/01/ - 09/30/12	07/01/ - 09/30/11	∆ IN %
	KEUR	KEUR		KEUR	KEUR
Healthcare Software	40,993	35,332	16.0	14,181	12,942	9.6
Healthcare Service	2,814	3,104	-9.3	858	950	-9.7
Total	43,807	38,436	14.0	15,039	13,892	8.3

Staff

NEXUS-Group employed a total of 482 people as of 30 September 2012 (Q3-2011: 468 employees). The great majority of the employees (453) work in the Healthcare Software segment (Q3-2011: 435). The Health Care Service segment employed 29 people (Q3-2011: 33).

Intelligent diagnosis by E & L: NEXUS strengthens product portfolio for diagnostic departments

NEXUS AG acquired 95% of the shares of E&L medical systems GmbH, Erlangen as of 17 October 2012. With approx. 70 employees and sales of about 5.0 million euros, the company is the market leader in the area of diagnostic software in Germany. More than 400 hospitals in Germany work using the software Clinic WinData (CWD) from E&L in the areas of endoscopy, cardiology, sonography and other wards requiring intensive diagnostic evaluations.

NEXUS and E&L collectively have a wide and very attractive diagnostic product Line

The wide range of diagnostic products of NEXUS has been expanded even further thanks the acquisition of E&L. «Together with the E&L product range, we provide the complete spectrum of special diagnostic evaluation systems,» Ralf Heilig (Sales Management Board at NEXUS) commented on the development. The previous focal points of the diagnostic products of NEXUS, radiology, gynecology, radiotherapy and pathology, are now be supplemented by a uniform diagnostic system for additional, essential diagnostic areas. These include endoscopy, cardiology, oncology, cardiac catheters and other special diagnostic modules. The strength of the solutions lies in equipment integration and intelligent diagnostic support for doctors The function supporting doctors especially helped to make the product CWD become the market leader.

E&L will continue as eigenstäniges Unterehmen and is in cooperation with other KIS manufacturers as a model in the NEXUS-Group

The company E+L and the product Clinic WinData will be managed as an independent company within the NEXUS-Group. This is in keeping with our previous strategy of also marketing diagnostic components independently of NEXUS / HIS. Consequently, a cooperative relationship with other participants on the market, such as E&L already practices today, is increasingly becoming the model of the NEXUS-Group. «We see potential in the collaboration with NEXUS and with our other partners to speed up the widespread usage of CWD substantially,» Edgar Lehmann (Managing Director of E&L GmbH) said about the future outlook of the company.

NEXUS will of course integrate the E&L products without interface into NEXUS / HIS. As a result, the already extremely successful HIS on the German market will be upgraded further and become attractive for additional clinical areas.

ASS.TEC GmbH: Process and SAP consultants play a more important role

With the acquisition of ASS.TEC GmbH 8 October 2012, NEXUS has further increased its involvement in the area of Process and SAP-ERP Consulting. NEXUS is already active intensively in both areas and considers them increasingly significant in software introductions. ASS. TEC GmbH has been active in SAP and Process Consulting for many years and supplements the skills of NEXUS ideally in this area. The consultants at ASS.TEC will continue to work in their traditional business areas and with their regular customers as well as additionally support the activities at customers of NEXUS. This is a combination that will also result in new solutions in mobile data recording of services and nursing work. As a result, NEXUS is closing a know-how and innovation gap and opening up new business areas.

New expertise in SAP and ARIS environment

The consultants are ASS.TEC remain active in their traditional areas of business and customers and support the activities in the NEXUS customers additionally. A combination that will lead to new solutions for mobile data capture services and care services. This concludes NEXUS know-how and innovation gap and open for new business. «We are confident that we will delight you with the expertise in the ASS.TEC around SAP and ARIS new customer groups for us,» said Martin Matuschyk, Managing NEXUS / IT alignment of the future of the area.

Sales by regions	01/01/ - 09/30/12	01/01/ - 09/30/11	∆ IN %	07/01/ - 09/30/12	07/01/ - 09/30/11	∆ IN %
	KEUR	KEUR		KEUR	KEUR
Germany	24,042	21,717	10.7	8,924	8,147	9.5
Switzerland	16,515	14,247	15.9	5,114	4,768	7.3
Austria	862	1,078	-20.0	269	244	10.2
Italy	7	7	0.0	0	2	-100
Rest of World	2,381	1,387	71.7	721	731	-1.4
Total	43,807	38,436	14.0	15,039	13,892	8.3

Chances and Risks

Please refer to the explanations in the annual report of 31 December 2011 for information about the essential chances and risks in the development of NEXUS Group. There have been no essential changes in the meantime.

Forecast: Continued Optimistic Outlook

NEXUS AG is changing. In addition to the challenges of organic growth of the past years, increasingly more tasks are required due to the building up of new business areas and the integration of new companies. The NEXUS team again worked very successfully in this intensive growth phase in the first nine months of 2012. We were able to continue the positive development of sales and result of the past years. We have achieved an outstanding result with sales increases of 14.0% and an improved result before taxes of 20.3%. This is specifically positive, because the expenses of our expansion strategy, especially the building up of new business areas, are completely consolidated in the results.

Against this background, we are moving ahead in the fourth quarter with a lot of confidence. However, we realize at the same time that the parallel challenges in our on-going customer projects and the building up of new business areas are very demanding.

The NEXUS Team is eager to face these challenges. We also know, however, that we can only achieve our goals this year if we are successful in all aspects. The prerequisites are good: The long-term strategy of our business, our strong product portfolio and the high number of orders on hand will help us to stay on a course of success.

The fact that the securities market is rewarding our positive development further with increasing stock prices and strong demand is very pleasing news. We are absolutely determined to support our positive development on the securities market with continually increasing business figures.

DIRECTORS`HOLDINGS	Number of stock owned	Number of options
Supervisory Board
Dr. jur. Hans-Joachim König	101.239 Prev. year (101.239)	0 Prev. year (0)
Prof. Dr. Alexander Pocsay	121.500 Prev. year (121.500)	0 Prev. year (0)
Erwin Hauser	15.000 Prev. year (15.000)	0 Prev. year (0)
Diplom-oec. Matthias Gaebler	0 Prev. year (0)	0 Prev. year (0)
Diplom-Betriebswirt (FH) Wolfgang Dörflinger	0 Prev. year (0)	0 Prev. year (0)
Prof. Dr. Ulrich Krystek	0 Prev. year (0)	0 Prev. year (0)
Executive Board
Dr. Ingo Behrendt, Dipl. Inf. Wiss. (MBA)	169.000 Prev. year (169.000)	0 Prev. year (0)
Ralf Heilig Dipl. Betriebswirt (FH), (MBA)	135.350 Prev. year (135.350)	0 Prev. year (0)
Edgar Kuner Dipl.-Ingenieur	248.051 Prev. year (253.051)	0 Prev. year (0)

NEXUS in the environment of financial and health markets

Finance- and Event schedule 2012/13 (status quo: November `12)

12. - 14. November
18. - 20. Januar 2013
9. - 11. April 2013
9. - 11. April 2013
9. - 11. April 2013
28. - 30. May 2013
29. May - 01. June 2013

NEXUS shares started the year 2012 at a listed price of € 7.00. The price increased to above € 7.50 at the end of January. Further ongoing first quarter share price ranged at about € 7.99 and € 8.58 mark. Followed by common stock price depression NEXUS-shares started a period of consolidation with prices of € 8.45 down to € 6.70. NEXUS-shares rised by publishing Half Year Report on August, 20th, up to 26.5% until beginning of October. In this period share prices increased from € 7.40 to € 9.36. Share-performance currently is on this level. Increasing of capital on November 8th, 2012, up to a capital of 15,105,150 € didn't influence the price of NEXUS-shares.

Decisions for NEXUS-solutions Q3-2012

• • August-Bier-Klinik, Bad Malente
• • Segeberger Kliniken, Bad Segeberg
• • LVR-Klinik, Bedburg-Hau
• • Justizvollzugskrankenhaus, Berlin
• • St. Josef-Hospital, Bochum
• • Knappschaftskrankenhaus Bottrop, Bottrop
• • Seniorenzentrum Am Kurler Berg, Dortmund Kurl
• • Diakonie-Krankenhaus Harz, Elbingerode
• • Zentrum für Psychiatrie Emmendingen, Emmendingen
• • Klinikum Fürth, Fürth
• • Kreiskrankenhaus Greiz, Greiz
• • Institut für diagnostische Histopathologie und Zytologie, Hamburg
• • Klinikum Ludwigsburg-Bietigheim, Ludwigsburg-Bietigheim
• • Evangelisches Fachkrankenhaus, Neustadt
• • Privatklinik Dr. Amelung, Königstein
• • Vorwerker Diakonie, Lübeck
• • Gemeinschaftspraxis Pathologie Dr. D. Dienemann, Dr. J. Hoelzl, Dr. S. Eisenlohr, München
• • Frauenklinik der Universitätsklinik Münster, Münster
• • Kreiskrankenhaus Prignitz, Perleberg
• • Pathologie Bethesda-Krankenhaus, Duisburg
• • LVR-Klinik, Langenfeld
• • Kreisklinik Jungenheim, Seeheim-Jugenheim
• • Kreiskrankenhaus Stollberg, Stollberg
• • Harz-Klinikum Wernigerode-Blankenburg, Werningerode
• • DREAM Pflegeheim, Winzenburg
• • Fachklinik Marienborn, Zülpich
• • Fachklinik für Psychiatrie und Psychotherapie Zülpich, Zülpich
• • Geriatriezentrum Graz, Graz (A)
• • Landesklinikum Horn, Horn (A)
• • Alten- und Pflegeheim der Barmherzigen Brüder, Kritzendorf (A)
• • Compass Seniorenwohnheim, Maria Lankowitz ( A)
• • adcura mobile Pflege und Betreuung, Wien (A)
• • Hópital de Villefranche-sur-Saone, Villefranche-sur-Saone (F)
• • Hópital Saint-Dié via Softway Médical (F)
• • Centre hospitalier Gabriel-Martin, Saint Paul Cedex (F)
• • Alters- und Pflegeheim, Adliswil (CH)
• • Betagtensiedlung D'r Heimä, Giswil (CH)
• • Seniorhuus Maiegrün, Hägglingen (CH)
• • Haus Tabea, Horgen (CH)
• • Altersheim Schweizerhof, Kandersteg (CH)
• • Heim Ibenmoos, Kleinwangen (CH)
• • Bethesda Alterszentren AG, Küsnacht (CH)
• • ThurVita AG, Wil (CH)
• • Alters- und Pflegeheim Notkerianum, St. Gallen (CH)

Facts and Figures Group P+L Account as of 09/30/2012 and 09/30/2011 (IFRS)

Consolidated Profit and Loss Account	01/01/ - 09/30/12	01/01/ - 09/30/11	07/01/ - 09/30/12	07/01/ - 09/30/11
	KEUR	KEUR	KEUR	KEUR
Revenue	43,807	38,436	15,039	13,892
Increase / decrease in finished goods and work in progress	6	-1	2	-1
Other capitalized company work	3,316	3,395	1,260	1,183
Other operating income	1,506	1,123	213	219
Cost of materials	8,579	6,632	3,210	2.749
Personnel expenses	24,165	21,226	7,709	7,690
Depreciation and amortization of fixed intangible and tangible assets	4,567	4,596	1,542	1,632
Other operating expenses	7,339	7,130	2,817	2,296
Operating Income	3,985	3,369	1,236	926
Expenses from associated companies	0	2	0	0
Interest and similar income	362	292	82	59
Interest payable and other similar charges	48	90	-3	71
profit before tax	4,299	3,573	1,321	914
Income taxes	-52	-57	-157	-42
Period result	4,351	3,630	1,478	956
The result for the period attributable to: - Shareholders of NEXUS AG - Non-controlling shareholders	4,641 -290	3,560 70	1,668 -190	973 -17
Period Result per share in KEUR
Weighted Average of Issued Shares in Circulation (in Thousands) - simple - diluted	14,246 0.33 0.33	14,207 0.26 0.26	14,246 0.12 0.12	14,207 0.07 0.07

Konzern-Gesamtergebnisrechnung

vom 30.09.2012 und 30.09.2011

Consolidated Profit and Loss Account in KEUR	01/01/ - 09/30/12	01/01/ - 09/30/11	07/01/ - 09/30/12	07/01/ - 09/30/11
Remaining Period result	4,351	3,630	1,478
Actuarial profits and losses (after taxes on profit)	-28	-106	0	-204
Differences from the conversion of foreign currency	-279	210	-225	-273
Market value changes from assets available for sale (after taxes on profit)	0	183	0	182
Other overall Result	-251	287	-225	-295
Overall Result of ther Period	4,100	3,917	1,253	661
Of the period result, attributed to: - Stockholders of NEXUS AG - Minority interests	4.390 -290	3.847 70	1.443 -190	678 -17
Of the overall result, attributed to: - Stockholders of NEXUS AG - Minority interests		3,847 70		678 -17

Facts and Figures Balance sheet as of 09/30/2012 and 12/31/2011 (IFRS)

Assets	09/30/2012	12/31/2011
	KEUR	KEUR
Long-term capital
Goodwill	20,107	18,433
Other intangible assets	17,689	18,231
Fixed Assets	1,841	1,762
Shares in affiliated companies	90	90
Credited deferred taxes	3,052	3,033
Other financial assets	40	74
Total long-term capital	42,819	41,623
Short-term capital
Inventories	597	132
Trade receivables and other receivables	13,322	14,364
Receivables from tax on profits	96	52
Other non-financial assets	1,480	903
Other financial assets	1,592	1,254
Kurzfristige Finanzanlagen	10,114	10,056
Cash and balance in bank	13,726	12,033
Total Short-term capital	40,927	38,797
Total Assets	83,746	80,420

Facts and Figures Balance sheet as of 09/30/2012 and 12/31/2011 (IFRS)

Total Liabilities	09/30/2012	12/31/2011
	KEUR	KEUR
Equity capital attributable to stockholders Of the parent company
Subscribed capital	14,305	14,305
Capital reserve	19,328	19,553
Net profit for the year	18,622	19,155
Gewinnrücklage	3,900	0
Konzernjahresüberschuss	4,641	4,770
Other cumulated Group result	-118	134
Own shares	-80	-46
Equity capital attributable to stockholders of the parent company	60,598	57,871
Minority interest	-6	284
Total Equity	60,592	58,155
long-term liabilities
Pension provisions	1,925	1,884
Deferred taxes	1,440	1,425
Other financial liabilities	523	1,707
Total long-term liabilities	3,888	5,016
Short-term liabilities
Deferments	1,653	1,380
Financial liabilities	78	88
Trade accounts payable	3,783	3,444
Liabilities from tax on profit	1,326	172
Deferred revenue liability	3,245	2,188
Other non-financial debts	5,047	7,107
Other financial debts	4,134	2,870
Total Short-term liabilities	19,266	17,249
Total equity and liabilities	83,746	80,420

Cash Flow for the period from January 1 to September 30, 2012 and 2011	2011	2010
	KEUR	KEUR
1, Cash Flow from operating activities
Profit before tax	4,351	3,573
Depreciation and amortization of intangible assets and plant, equipment and other fixed assets	4,567	4,596
Other expenses / income with no impact on cash	-58	51
Depreciation of financial assets	-461	78
Profit / loss from disposal of long term capital	778	2,052
Profit / loss from disposal of securities	206	-64
Increase / decrease in trade receivables and other assets that cannot be allocated to investing or financing activities	-1,961	-1,993
Interest paid	-48	-13
Interest received	362	348
Income tax payments	-80	-56
Interest payments received	7	90
	7,663	8,662
2, Cash Flow from INvestment activities
Cash paid for investments in property, plant and equipment / intangible assets	-4,217	-3,395
Cash paid from purchase price adjustments at subsidiaries	0	-5,433
	-4,217	-8,828
3, Cash Flow from financing activities
Capital increase in return for stock	0	134
Addition to capital reserves in return for stock	0	800
Payments for taking loans within the context of short-term payment disposal	-305	0
Auszahlung Dividende	-1,428	0
Payments for repayments of loans	-10	0
	-1,743	934
4, Cash and cash equivalents at end of fiscal year
Cash-relevant changes in cash and cash equivalents (sum of 1 + 2 + 3)	1,703	768
Cash and cash equivalents at beginning of fiscal year	11,945	18,575
	13,648	19,343
5, Comp osition of cash and cash equiva lents
Cash on hand	13,726	19,501
Bank liabilities due on demand	-78	-158
	13,648	19,343

Facts and Figures Development of Group Equity as of 09/31/2012 and 09/31/2011 (IFRS)

development of group equity

group equity
	Subscribed capital	Capital reserves	Other provisions	Equity diference from curency conversion	Reserve for financial Instruments	Reserve for pensions	onsolidated loss carry forward	deficit / profit Consolidated	Treasury Stock	Equity cap , attributable to stockh, of parent company	Minority interest	Total equity	Authorized capital
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR 13
Consolidated equity as of 12/31/2011	14,171	18,778	0	916	-10	-630	15,816	3,447	-26	52,462	334	52,796	6,622
Transfer of 2010 consolida ted loss to consolidated loss carry-forward							3,447	-3,447
Recognized directly in other comprehensive income				-210	-183	106			-1	-288		-288
Sonstiges Gesamtergeb nis	0	0	0	-210	-183	106	3,447	-3,447	-1	-288	0	-288
Consolidated net income for 2011								3,700		3,700	68	3,768
Overal Result of the period				-210	-183	106	0	3,700	-1	3,412	68	3,480
Share capital increase	134	800								934		934	-134
Equity 09/31/2011	14,305	19,553	0	706	-193	-523	19,263	3,700	-27	56,812	402	57,214	6,488
Equity 12/31/2011	14,305	19,553	0	1,192	0	-1,058	19,155	4,770	-46	57,871	284	58,155	6,488
Setting the Group's net profit in 2011 the loss carry forward							4,770	-4,770
Recognized directly in other comprehensive income				-279		-28				-307
Consolidated net income 09/30/2012								4,641		4,641	-236	4,405
Overal Result of Periode 2012	14,305	19,553	0	913	0	-1,087	23,925	4,641	-46	62,253	48	62,253	6,488
Increase the authorized capital (HV 2011)													665
Allocation to retained ear nings vs. HV			3,900				-3,900
Dividend payment							-1,428			-1,428		-1,428
Purchase common shares		-225					25		-34	-234		-234
Equity 09/30/2012	14,307	19,328	3,900	913	0	-1,087	18,622	4,641	-80	60,542	48	60,592	7,153

Declaration according to § 37y No. 1 WpHG

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view ot the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description ot the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Villingen-Schwenningen, November 12, 2012

NEXUS AG Executive Board

NEXUS AG, Auf der Steig 6, D-78052 Villingen-Schwenningen Telefon +49 (0)7721 8482 -0, Fax +49 (0)7721 8482-888 www.nexus-ag.de, info@nexus-ag.de